[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anxiety-state\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anxiety-state":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,41,71,100,128,149,173,197],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100535006","from-prevention-to-treatment-how-biological-rhythms-can-maintain-perinatal-mental-health-100535006",false,"NCT06246214","From Prevention to Treatment: How Biological Rhythms Can Maintain Perinatal Mental Health","Innovations in Biological Rhythms in the Context of Mental Health: Effectiveness of New Technologies and Exposure to Different Lighting Patterns in Women During the Postpartum Period","Inclusion Criteria:\n\n* 4-6 weeks postpartum;\n* Postnatal depression confirmed through Edinburgh Postnatal Depression Scale (EPDS) \\> 10;\n* Mini-International Neuropsychiatric Interview (M.I.N.I.) positive for current depressive episode.\n\nExclusion Criteria:\n\n* Active suicidal ideation;\n* Psychotic symptoms;\n* Unstable general medical conditions that interfere with the acquisition of actigraphy;\n* Newborn with severe health conditions (hospitalization, care in the neonatal ICU).","FEMALE","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","Depression and anxiety are significant public health issues during pregnancy and the postnatal period, particularly affecting those in developing countries. Disruptions in biological rhythms, sleep problems, and low exposure to daylight are associated with a higher risk of these mental health issues. The perinatal period poses unique challenges to the temporal program, with evidence indicating that sleep disturbances significantly increase the risk of postnatal depression. A Randomised Clinical Trial (RCT) is being conducted to assess the effectiveness of Blue Light Therapy (BlueLT) in treating depressive and anxiety symptoms during the postpartum. The RCT will also investigate the alignment of rest-activity and internal body time as mediating factors. This study will focus on various chronobiological factors, including rest-activity rhythms, light exposure levels, temperature rhythms, sleep duration and phase, social jetlag, and BodyTime (assessed through a single blood sample). The goal is to recruit 50 women with postpartum depression, with 25 in the BlueLT intervention group and 25 in the ControlLT placebo group, alongside 100 healthy controls. The BlueLT device uses a short-wavelength LED lamp mainly composed by a wavelength peak on blue spectrum, while the ControlLT device has a dim long-wavelength LED. A Healthy Control group will also be included to account for changes unrelated to depression diagnosis or placebo\u002Ftreatment effects. Exclusion criteria involve a history of major depressive or anxiety disorder, current psychotic disorder, night shift work, active suicidal thoughts, unstable medical conditions interfering with data collection, and newborns with severe health conditions. The study aims to evaluate the impact of BlueLT on postpartum depression and understand the role of chronobiological factors in the health\u002Fdisease process.",[26,27],"Depression, Postpartum","Anxiety State","RECRUITING","2025-11-25",{"date":31,"type":32},"2025-12-03","ACTUAL",{"date":34,"type":32},"2024-01-04",{"date":36,"type":20},"2027-05",{"name":38,"class":39},"Hospital de Clinicas de Porto Alegre","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":40},"100604532","exercise-assisted-ergonomic-training-for-pain-sleep-and-anxiety-in-nursing-students-rct-100604532","NCT07150741","Exercise-Assisted Ergonomic Training for Pain, Sleep, and Anxiety in Nursing Students: RCT","The Effect of Exercise-Assisted Ergonomic Training on Pain, Sleep Quality, and Anxiety Levels in Nursing Students: A Randomized Controlled Trial","EASE","Inclusion Criteria:\n\n* Being a student in the Nursing Department of Kütahya Health Sciences University.\n* Willingness to participate in the study voluntarily.\n* No chronic diseases preventing exercise (e.g., COPD, heart failure).\n* No hearing impairments.\n* No psychiatric diagnosis (e.g., major depression, anxiety disorders) and not using related medications.\n* Ability to use a smartphone (iOS or Android) and have internet access.\n* No neurological, systemic, or psychiatric disorders.\n\nExclusion Criteria:\n\n* Students unwilling to participate in the study.\n* Developing any health problem during the intervention period.\n* Unable to continue participation for any reason.\n* Voluntarily withdrawing from the study.\n* Pain level above 5 on the Numeric Pain Rating Scale at baseline; such participants will be referred to a physiotherapist.\n* Any adverse events during exercise sessions (e.g., sudden pain, dizziness, fatigue, blood pressure changes) will result in immediate cessation of the exercise, monitoring of the participant, and referral to the nearest healthcare facility if necessary. Emergency first aid will be provided if needed, and the responsible researcher will contact the relevant health services immediately.",true,"ALL","30 Years",{"count":53,"type":20},60,[23],"This randomized controlled trial aims to evaluate the effect of exercise-assisted ergonomic training on pain, sleep quality, and anxiety levels among nursing students. The study population consists of students enrolled in the Nursing Department of Kütahya Health Sciences University. Sixty participants will be recruited according to inclusion criteria and randomly assigned into intervention and control groups.\n\nThe intervention group will receive a structured ergonomic training program combined with exercise sessions, including theoretical lectures and practical exercise videos delivered twice a week for four weeks. The control group will continue with their standard nursing curriculum without additional ergonomic or exercise support. Data will be collected using the Numeric Pain Rating Scale, Pittsburgh Sleep Quality Index, and State Anxiety Inventory before and after the intervention.\n\nThe study is expected to provide evidence on the effectiveness of ergonomic and exercise-based strategies in reducing pain, improving sleep quality, and lowering anxiety among nursing students, supporting the integration of such programs into nursing education.",[57,58,27],"Pain","Sleep",[60],"Pain, Sleep Quality, Anxiety","NOT_YET_RECRUITING","2025-08-25",{"date":64,"type":32},"2025-09-02",{"date":66,"type":20},"2025-09-15",{"date":68,"type":20},"2025-12-30",{"name":70,"class":39},"Kutahya Health Sciences University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":40},"100602583","low-level-laser-auriculotherapy-in-the-treatment-of-myogenic-temporomandibular-disorders-and-anxiety-100602583","NCT07125404","Low-Level Laser Auriculotherapy in the Treatment of Myogenic Temporomandibular Disorders and Anxiety","Effectiveness of Low-Level Laser Auriculotherapy in the Treatment of Myogenic Temporomandibular Disorders and Anxiety: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of unilateral or bilateral myogenic temporomandibular disorder (TMD) based on DC\u002FTMD criteria.\n* Presence of myalgia or myofascial pain in the masticatory muscles, either spontaneous or induced by clinical palpation.\n* At least one episode of local, referred, or radiating masticatory pain in the past 30 days, lasting at least one hour.\n* Score ≥ 5 on the Generalized Anxiety Disorder 7-item scale (GAD-7), indicating generalized anxiety.\n\nExclusion Criteria:\n\n* Recent musculoskeletal injury in the cervical region.\n* Skin lesions or dermatological conditions on the auricle.\n* Regular use of medications such as corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), or photosensitizing agents (e.g., tetracyclines, quinolones, sulfonamides).\n* Tattoos on or near the auricular area.\n* History of cancer or tumors within the past five years.\n* Fitzpatrick skin phototype V or VI.\n* Autoimmune diseases (e.g., lupus erythematosus, hepatic porphyria, pellagra).\n* Epilepsy.\n\nDiscontinuation Criteria\n\n\\- The participant's withdrawal or non-attendance results in the failure to complete the evaluation or treatment protocol.",{"count":79,"type":20},32,[23],"Summary:\n\nLow-level laser auriculotherapy (LLLT-AT) is a non-invasive technique that has gained attention for managing musculoskeletal pain and anxiety. Given the painful and emotional components of temporomandibular disorders (TMD), LLLT-AT may offer therapeutic benefits by stimulating auricular points associated with pain modulation and anxiety reduction. This randomized, placebo-controlled, two-arm clinical trial with blinded outcome assessors aims to evaluate the effects of LLLT-AT in individuals diagnosed with myogenic TMD (Axis I, Group I of the DC\u002FTMD classification) and anxiety. The study will be conducted at the Physical Agents Laboratory of Universidad Andrés Bello. Eligible participants will include members of the university community with myogenic TMD (Axis I, Group I of the DC\u002FTMD classification) and anxiety. Participants will be stratified by sex and randomly assigned to either an experimental group receiving LLLT-AT combined with a standardized myofascial release protocol or a control group receiving sham LLLT-AT with the same myofascial protocol. Interventions will be administered twice weekly for three weeks. Outcome measures will be collected at baseline, post-intervention, and at a four-week follow-up. Primary outcomes include pressure pain threshold (PPT), assessed by algometry, and anxiety level, measured using the GAD-7 scale. Secondary outcomes include maximum mouth opening range of motion (MMOROM) and mandibular functional limitation (MFL), assessed using the Jaw Functional Limitation Scale 8 (JFLS-8).",[83,27],"Temporomandibular Disorder",[85,86,87,88,89,90],"Laser Therapy","Low-level Light Therapy","Auriculotherapy","Joint Disorders","Temporomandibular Joint Dysfunction Syndrome","Anxiety","2025-08-12",{"date":93,"type":32},"2025-08-15",{"date":95,"type":20},"2025-09-01",{"date":97,"type":20},"2026-05-01",{"name":99,"class":39},"Quiropraxia y Equilibrio",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":49,"sex":50,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100548228","the-effect-of-therapeutic-play-on-anxiety-and-fear-levels-in-children-with-diabetes-100548228","NCT06418269","The Effect of Therapeutic Play on Anxiety and Fear Levels in Children With Diabetes","The Effect of Insulin Education Given to Children With Diabetes by Therapeutic Play Method on Anxiety and Fear Levels","Inclusion Criteria:\n\n* The child must be between the ages of 9 and 12 (since the State Anxiety Inventory for Children Scale is for this age range)\n* Diagnosed with type 1 diabetes\n* Absence of mental retardation\n* Receiving subcutaneous insulin treatment for the first time\n* Voluntariness of the child and parent to participate in the study\n\nExclusion Criteria:\n\n* Visual, hearing or speech impairment\n* Illiteracy of the child\n* Having a clinical condition that prevents playing games (excessive fatigue, weakness, etc.)","9 Years","12 Years",{"count":53,"type":20},[23],"The study will be conducted using a randomized controlled method. Children with type 1 diabetes who are admitted to the Pediatric Endocrinology Service will be divided into two groups by randomization method. Following randomization, children in the experimental group will play a therapeutic game before their subcutaneous insulin treatment. In the subcutaneous insulin treatment of the children in the control group, the routine practice of the clinic will be applied. Anxiety and fear levels of all children in the experimental and control groups will be evaluated before and after subcutaneous insulin treatment.",[113,114,115,27],"Type1diabetes","Therapeutic Play","Fear State",[113,117,118,27],"Therapeutic play","Fear state","2025-04-29",{"date":121,"type":32},"2025-04-30",{"date":123,"type":20},"2025-07-18",{"date":125,"type":20},"2026-08-18",{"name":127,"class":39},"Istanbul University - Cerrahpasa",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":40},"100543649","evaluation-of-an-anxiety-reduction-tool-during-thyroid-biopsies-100543649","NCT06358612","Evaluation of an Anxiety Reduction Tool During Thyroid Biopsies","Evaluation of An Anxiety Reducing Tool During Thyroid Biopsies: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Subjects undergoing thyroid biopsies under local anesthetic that can provide consent to treatment and for the research study.\n\nExclusion Criteria:\n\n1. Previous biopsy experience\n2. Greater than one (1) thyroid lesion requiring biopsy\n3. Known allergy or sensitivity to stress ball material or cleaning solutions.",{"count":136,"type":20},300,[23],"Patients undergoing thyroid biopsy under local anesthetic will be asked to fill out a questionnaire that evaluates their anxiety level before and after their procedure. Patients will be randomly assigned to either use an anxiety reducing tool (stress balls in each hand) to take their mind off the procedure or will not receive an anxiety reducing tool.",[27],"2025-02-14",{"date":142,"type":32},"2025-02-18",{"date":144,"type":32},"2024-12-01",{"date":146,"type":20},"2025-12-31",{"name":148,"class":39},"Nova Scotia Health Authority",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":169,"leadSponsor":171,"locationsCount":40},"100569733","the-effect-of-using-multimedia-during-the-informed-consent-process-on-the-anxiety-of-parents-of-orchiopexy-patients-100569733","NCT06698081","The Effect of Using Multimedia During the Informed Consent Process on the Anxiety of Parents of Orchiopexy Patients","The Effect of Using Multimedia During the Informed Consent Process on the Anxiety of Parents of Orchiopexy Patients: a Randomized Controlled Trial","Inclusion Criteria:\n\n* parents of orchiopexy patients\n\nExclusion Criteria:\n\n* history of previous orchiopexy surgery\n* orchiopexy with other surgical procedures ( f.e. Hypospadias repair)",{"count":157,"type":20},70,[23],"Aim: The goal of this randomized controlled trial is to detect the effect of using multimedia during the informed consent process on the anxiety of parents of orchiopexy patients.\n\nParents (primary caregivers) of the patients who underwent orchiopexy surgery are included in the study.\n\nThe main question it aims to answer is:\n\n• Does the use of multimedia during the preoperative consent process affect the anxiety level of parents of patients undergoing orchiopexy surgery?",[161,27],"Undescended Testis",[163,164],"undescended testis","anxiety state","2024-11-19",{"date":167,"type":32},"2024-11-20",{"date":167,"type":20},{"date":170,"type":20},"2025-03-28",{"name":172,"class":39},"Marmara University",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":195,"locationsCount":40},"100560452","music-therapy-on-state-anxiety-levels-and-well-being-during-chemotherapy-100560452","NCT06577324","Music Therapy on State Anxiety Levels and Well-being During Chemotherapy","Effect of a Single Session of Live Group Music Therapy on State Anxiety Levels and Well-being During Chemotherapy: A Multicenter Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients with a cancer diagnosis, attending intravenous chemotherapy sessions at the Sebastián de Belalcázar and del Carmen clinics.\n* Patients over 18 years old.\n* Patients who have never previously received music therapy.\n* Patients with literacy skills.\n\nExclusion Criteria:\n\n* Patients who report having hearing problems.\n* Patients who express a desire not to participate in the study.\n* Patients with difficulties understanding and completing questionnaires.",{"count":181,"type":20},102,[23],"Introduction: Many cancer patients experience high levels of anxiety during chemotherapy, which can negatively impact their mental health and physiological, emotional, and spiritual well-being. Various complementary therapies exist to mitigate these effects, including music therapy. Although preliminary evidence supports the positive effects of music therapy and music-based interventions in chemotherapy, few studies report live group interventions conducted by accredited music therapists.\n\nObjective: To determine the effect of a single session of live group music therapy on state anxiety levels and well-being in adult cancer patients undergoing chemotherapy.\n\nMethodology: This study is a multicenter, randomized clinical trial with two arms. The intervention group will receive standard care plus a live group music therapy session, while the control group will receive standard care only. The primary outcome measure is the State-Trait Anxiety Inventory (STAI-E), and the secondary outcome measure is well-being, assessed using the Well-being Numerical Rating Scales (WB-NRSs). The scales will be administered before and after each intervention. The sample size is 102 patients.\n\nExpected Results: This study aims to improve the psycho-emotional health and well-being of cancer patients during chemotherapy, thereby enhancing the quality of care.",[27,185],"Well-Being, Psychological",[90,187,188],"Well-Being","Music Therapy","2024-08-27",{"date":191,"type":32},"2024-08-29",{"date":193,"type":20},"2024-09-01",{"date":95,"type":20},{"name":196,"class":39},"Claudia Aristizábal",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":40},"100530462","the-supplementation-therapy-in-autism-and-response-to-treatment-study-100530462","NCT06187090","The Supplementation Therapy in Autism and Response to Treatment Study","The Supplementation Therapy in Autism and Response to Treatment (START) Study","START","Inclusion Criteria:\n\n* Individuals diagnosed with Level 1 ASD, as defined using Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5);\n* Aged 18-35 years;\n* To be able to understand and communicate in Italian;\n* To be able to give informed consent.\n\nExclusion Criteria:\n\n* Level 2 or Level 3 ASD, as defined using Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) \\[47\\];\n* Current diagnosis of a co-occurring major psychiatric disorder (e.g., major depressive disorder, bipolar affective disorder, psychotic disorders);\n* Active suicidal ideation indicating significant current risk or history of serious suicide attempt in the opinion of the PI, as evaluated at the screening stage;\n* Lifetime neurological disorders (e.g., epilepsy, except febrile convulsions) or severe intercurrent physical illness;\n* Current treatment with psychotropic medication, with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) stable monotherapy (at least 8 months);\n* IQ \\\u003C 70;\n* Female patients who are pregnant, lactating or not using an acceptable effective form contraception if they are at risk of falling pregnant;\n* Taking part in another pharmacological trial.","35 Years",{"count":207,"type":20},20,[23],"In addition to the \"core\" symptoms of ASD (i.e., impaired communication, impaired reciprocal social interaction and restricted, repetitive and stereotyped patterns of behaviors or interests), it is estimated that up to 70% of autistic people present at least one comorbid psychiatric disorder, leading to a deterioration in quality of life, a greater demand for support and worse prognosis and outcome. Anxiety and depressive symptoms would seem to be more present in individuals with Level 1 ASD, requiring their prioritisation against core symptoms. To date, the first-line treatment for autistic patients with comorbid depressive and\u002For anxiety symptoms is still debated and it is not always clear whether they may or may not benefit from psychotherapeutic and conventional psychopharmacological approaches. As such, growing evidence strengthens the therapeutic potential of the endocannabinoid (eCB) system modulation and of eCB-like compounds.\n\nThe aim of this study is to provide a response to an unmet clinical need in this framework of psychic vulnerability by initiating oral therapy with palmitoylethanolamide (PEA), a nutraceutical\u002Ffood supplement with proven anti-inflammatory and neuroprotective properties.\n\nIndeed, many conditions of psychological distress are thought to be underpinned by systemic inflammatory and\u002For neuroinflammatory processes, on which PEA has shown remarkable efficacy, including through modulation of the immune response and the interaction between the endocannabinoid system and the gut-microbiota-brain axis.\n\nThe trial we are proposing is a 12-week open-label phase 2 study involving the daily intake of PEA 600 mg, at a dosage of 1 tablet\u002Fday.\n\nThis study will be conducted at the Unit of Psychiatry of Santa Maria della Misericordia Udine University Hospital.\n\nThrough this study, we wish to evaluate: the ability of PEA to alleviate symptoms of psychic distress (i.e., anxiety and\u002For depression) in Level 1 autistic adults; the safety and tolerability of sustained intake of PEA in Level 1 autistic adults; and the biological basis of PEA functioning.\n\nThe study involves taking PEA orally once daily (600 mg daily) at the same time as a meal during the initial 12-week phase. Upon completion of the initial phase, subjects will be offered to enter an extension phase of the trial of an additional 24 weeks to assess treatment stability, with the possibility of titration of PEA to 1200 mg daily based on observed clinical compensation. Each participant will be on PEA treatment for up to 36 weeks.\n\nDuring the course of the study, periodic clinical re-evaluations will be conducted at our Day-Hospital setting.\n\nThe trial will unfold through one screening visit, one baseline visit, and two follow-up visits (FUP, 4 weeks and 12 weeks apart). The patient will be administered standardized interviews by a qualified investigating physician; clinical objective examination, collection of blood and urine samples for standard hematochemical investigations, collection of blood and stool samples for analysis of some biological markers of interest, monitoring of adherence to therapy intake, side effects, and adverse effects will also be performed during the follow-up visits. The nutraceutical PEA will be dispensed by the clinical investigators at each follow-up visit.",[211,212,213,214,215,27],"Autism","Autism Spectrum Disorder","Autism Spectrum Disorder High-Functioning","Asperger Syndrome","Depressive Symptoms","2023-12-15",{"date":218,"type":32},"2024-01-02",{"date":220,"type":32},"2023-09-01",{"date":222,"type":20},"2026-11",{"name":224,"class":39},"University of Udine"]